Clinics and Research in Hepatology and Gastroenterology
Original articleEfficacy and safety of acetylcysteine in “non-acetaminophen” acute liver failure: A meta-analysis of prospective clinical trials
Introduction
Acute liver failure (ALF) is a life threatening disease, usually caused by alcohol intoxication, hepatitis virus infection, or hepatotoxic drugs and toxins. A recent survey has shown that acetaminophen overdose is the most frequent cause of ALF in the US [1]. Acetylcysteine (NAC) is the N-acetyl derivative of the amino acid cysteine and is the agent of choice to prevent hepatotoxicity associated with acetaminophen overdose. However, although NAC is currently used as off label for acetylcysteine in non-acetaminophen induced ALF (NAI-ALF), the efficacy is still inconclusive.
A number of double blind, randomized and multi-center clinical trials have been conducted to assess the efficacy of NAC on NAI-ALF in both adults and children. The first clinical trial was started in 1998 by the Acute Liver Failure Study Group, funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. It is a prospective, randomized, double-blind, placebo-controlled trial of NAC for adult NAI-ALF patients, which was conducted at 24 participating sites in the United states for eight years from 1998 to 2006 [2]. There was no difference in the overall survival at three weeks between NAC (70%) vs placebo groups (66%) (P = 0.238). However, transplant-free survival was significantly better in NAC patients with coma grades I–II who received NAC compared with placebo (52% vs 30%, P = 0.010); however, no difference was found in coma grades III–IV (P = 0.912). Another prospective study that enrolled 47 adult NAI-ALF patients also showed similar results, in which 22 patients (47%) survived in NAC group and 12 (27%) in control group (P = 0.05), indicating that NAC caused reduction in mortality [3].
However, other studies in pediatric patients demonstrated controversial results [4], [5]. The results of the study by Singh et al. [4] do not support the use of NAC for NAI-ALF because the survival between the NAC (73%) and placebo (82%) treatment groups was not statistically different. The 1-year transplantation-free survival was significantly lower (P = 0.03) in those who received NAC (35%) than those who received placebo (53%). Another retrospective study showed that NAC was associated with a shorter length of hospital stay, higher incidence of native liver recovery without transplantation, and better survival after transplantation [5].
There are a few causes for the discrepancy among the studies. The two studies in children groups are limited by the historical control groups in which the patients were not treated at the same time as in NAC group. Also, the patient population in Mumtaz et al.’s study [3] showed that the patients in NAC group were younger and their disease was more severe compared to the control group. Therefore, in order to draw solid conclusions about the efficacy of NAC for NAI-ALF patients, there is a need for further clinical trials in a larger number of patients.
The aim of this article is to evaluate the safety and efficacy of NAC in patients with ALF not caused by acetaminophen poisoning using meta-analysis method.
Section snippets
Database and search strategy
We searched the following database for relevant studies: PubMed (from 2000 to April 2014) and EMBASE (from 2000 to April 2014). Search terms used for PubMed are: “NAC” and “acute liver failure” or “acetylcysteine” and “acute liver failure”.
Study selection criteria and Quality assessment
Eligible studies were selected based on the following criteria:
- •
study design: prospective study;
- •
subjects: patient with NAI-ALF, including adults and children who were up to 18-year old
- •
intervention: NAC administered orally or intravenously.
Authors independently
Study identification and characteristics
A total of 15 unique records were identified by our search strategy. After initial screening by title and abstract, four relevant studies (2, 3, 5 and 10) were selected for full text retrieving (Fig. 1).
Primary and secondary outcome
Among these studies, a total of 331 patients receiving the treatment with NAC (oral or intravenously) and 285 patients in control group were included in the final statistical analysis. No statistical difference was identified between NAC group and control group for overall survival [236/331(71%)
Discussion
Our meta-analysis results show that intravenous NAC and oral NAC improved transplant-free survival and survival after transplantation in patients with NAI-ALF, however, it failed to improve the overall survival.
In comparing the length of hospital stay among survivors, a trend was observed for NAC-treated patients to have shorter hospital stays (median, 9 vs 13 days; P = .056) by Lee study [2]. Kortsalioudaki et al.’s study [5] reported the similar result that those children treated with NAC
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
References (10)
- et al.
Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure
Hepatology
(1996) - et al.
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States
Ann Intern Med
(2002) - et al.
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure
Gastroenterology
(2009) - et al.
Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation
Hepatol Int
(2009) - et al.
Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure
Dig Dis Sci
(2013)